Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
DUBLIN, Ireland, Feb. 01, 2016 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in two upcoming meetings:
- BIO CEO & Investor Conference on February 8, 2016 in New York, NY. Prothena President and Chief Executive Officer Dale B. Schenk, PhD will present an update on the company’s business at 10:00 AM ET and participate in a fireside chat at 1:30 PM ET.
- Leerink Partners 5th Annual Global Healthcare Conference on February 11, 2016 at 8:55 AM ET in New York, NY.
A live webcast of the presentations from both conferences can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, replays of the webcasts will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).
For more information, please visit the company's web site at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose 650-922-2405, [email protected]
